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With respect to a comparison of CAS and CEA, Roh et al. 3) demonstrated similar results seen in previous studies. The periprocedural stroke risk increased in CAS compared to CEA and periprocedural myocardial infarction risk increased or was similar in CAS compared to CEA. This result is in line with the 2017 ESC guidelines, which recommends CEA as the first treatment modality to be used in standard patients. The results of the MT and CAS comparison that demonstrated a trend for lower risk in CAS can be interpreted as CAS is better compared to MT in patients with asymptomatic carotid artery stenosis. However, as the authors clarified in their discussion, most analyzed studies regarding MT are mostly outdated. Previous studies which assessed MT for asymptomatic carotid artery stenosis report improved efficacy as the publication date is more recent. 6)7) The efficacy of potent contemporary MT regimens may be clarified to some degree in future studies such as the Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2) 8) and the Second European Carotid Surgery Trial (ECST-2), 9) which are future randomized trials.
Randomized trials which include a large number of patients will be essential to establish more well-described and updated clinical practices and guidelines for asymptomatic carotid artery stenosis. MTs for the disease include antiplatelet and lipid-modifying agents, and stroke risk factor management. Those drugs and management protocols have dramatically changed from the era of earlier studies on MTs. 7) Single antiplatelet therapy with aspirin has been the classic antiplatelet regimen. Other antiplatelet drugs (i.e., clopidogrel, ticagrelor, or prasugrel) are supported by no data at the current time. At this time, lipid-modifying agents include statins, ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors, icosapent ethyl, etc. The 2019 ESC/European Atherosclerosis Society (EAS) dyslipidemia guideline recommended low-density lipoprotein cholesterol level should be targeted below 55 mg/dL in very high risk patients. The accepted blood pressure goal has been changed since the Systolic Blood Pressure Intervention Trial (SPRINT). 10) These recently updated findings should be assessed in future studies. Some of these questions may be answered by the above mentioned CREST-2 and ECST-2, which are underway in North America and Europe, respectively.
There are limitations in the reviewed study that should be noted. The number of RCTs was relatively small with respect to overcoming heterogeneous patient data which included heterogeneous diagnosis modalities and stenosis severity.
Optimal treatment is a problem that has lingered for a long time, along with medical technology advances and paradigm changes with respect to this condition. Future studies may resolve some of the unanswered questions. However, there are pending questions at the moment and precision medicine methods will be necessary for decision making in asymptomatic carotid artery stenosis.
